Contineum Therapeutics (CTNM) EPS (Weighted Average and Diluted) (2023 - 2024)
Historic EPS (Weighted Average and Diluted) for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to -$0.57.
- Contineum Therapeutics' EPS (Weighted Average and Diluted) fell 6285.71% to -$0.57 in Q4 2024 from the same period last year, while for Dec 2024 it was -$1.71, marking a year-over-year change of. This contributed to the annual value of -$2.18 for FY2024, which is 282500.0% down from last year.
- Per Contineum Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.57 for Q4 2024, which was down 6285.71% from -$0.4 recorded in Q3 2024.
- In the past 5 years, Contineum Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.84 in Q2 2023 and a low of -$2.69 during Q3 2023